The Spectrum of Double Hit Lymphomas

被引：8

作者：

Abramson, Jeremy S. ^{[1
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, 55 Fruit St,Yawkey 9A, Boston, MA 02114 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2016年 / 30卷 / 06期

关键词：

Double-hit lymphomas; Double-expressing lymphomas; High grade B-cell lymphoma; MYC; BCL2; B-CELL LYMPHOMA; NON-HODGKIN-LYMPHOMA; CLINICAL PRESENTATION; MYC REARRANGEMENT; BURKITT-LYMPHOMA; GERMINAL CENTER; FEATURES; PROGNOSIS; RITUXIMAB; TRANSLOCATIONS;

D O I：

10.1016/j.hoc.2016.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Double-hit lymphomas (DHLs) characterize a unique subset of B-cell non Hodgkin lymphomas. DHL typically presents in older adults with high-risk clinical features. This entity carries a significantly inferior prognosis compared with typical cases of diffuse large B-cell lymphoma; however, emerging literature can identify discrete clinical features within DHL that are associated with a favorable prognosis. Emerging literature is also demonstrating that intensive upfront treatment strategies may improve outcome. Diagnosis, prognostication, and management of DHL are reviewed, as well as potential future directions incorporating novel biologically targeted therapies. Finally, double-expressing lymphomas (DELs) will be discussed and contrasted with DHL.

引用

页码：1239 / +

页数：12

共 37 条

[1] Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy [J].

Abramson, Jeremy S. ;

Barnes, Jeffrey A. ;

Feng, Yang ;

Takvorian, Tak ;

Neuberg, Donna S. ;

Hochberg, Ephraim P. ;

Sohani, Aliyah R. .

BLOOD, 2012, 120 (21)

[2] Intravenous Methotrexate as Central Nervous System (CNS) Prophylaxis Is Associated With a Low Risk of CNS Recurrence in High-Risk Patients With Diffuse Large B-Cell Lymphoma [J].

Abramson, Jeremy S. ;

Hellmann, Matthew ;

Barnes, Jeffrey A. ;

Hammerman, Peter ;

Toomey, Christiana ;

Takvorian, Tak ;

Muzikansky, Alona ;

Hochberg, Ephraim P. .

CANCER, 2010, 116 (18) :4283-4290

[3]

[Anonymous], 2015, BLOOD, DOI DOI 10.1182/blood.V126.23.1491.1491

[4]

[Anonymous], 2014, Blood, DOI DOI 10.1182/BLOOD.V124.21.291.291

[5] Double-hit B-cell lymphomas [J].

Aukema, Sietse M. ;

Siebert, Reiner ;

Schuuring, Ed ;

van Imhoff, Gustaaf W. ;

Kluin-Nelemans, Hanneke C. ;

Boerma, Evert-Jan ;

Kluin, Philip M. .

BLOOD, 2011, 117 (08) :2319-2331

[6] Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study [J].

Barnes, Jeffrey A. ;

Redd, Robert Allyn ;

Jacobsen, Eric D. ;

Fisher, David C. ;

Freedman, Arnold S. ;

Hochberg, Ephraim P. ;

Takvorian, Tak ;

Neuberg, Donna ;

Abramson, Jeremy S. .

BLOOD, 2014, 124 (21)

[7] Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab [J].

Barrans, Sharon ;

Crouch, Simon ;

Smith, Alex ;

Turner, Kathryn ;

Owen, Roger ;

Patmore, Russell ;

Roman, Eve ;

Jack, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3360-3365

[8] BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma [J].

Bhadury, Joydeep ;

Nilsson, Lisa M. ;

Muralidharan, Somsundar Veppil ;

Green, Lydia C. ;

Li, Zhoulei ;

Gesner, Emily M. ;

Hansen, Henrik C. ;

Keller, Ulrich B. ;

McLure, Kevin G. ;

Nilsson, Jonas A. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (26) :E2721-E2730

[9] Complete Response to Induction Therapy in Patients With Myc-Positive and Double-Hit Non-Hodgkin Lymphoma Is Associated With Prolonged Progression-Free Survival [J].

Cohen, Jonathon B. ;

Geyer, Susan M. ;

Lozanski, Gerard ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Hall, Nathan C. ;

Nagar, Veena A. ;

Hemminger, Jessica A. ;

Jones, Jeffrey A. ;

Porcu, Pierluigi ;

Christian, Beth A. ;

Baiocchi, Robert A. ;

Maddocks, Kami J. ;

Flynn, Joseph M. ;

Devine, Steven M. ;

Blum, Kristie A. .

CANCER, 2014, 120 (11) :1677-1685

[10] MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study [J].

Copie-Bergman, Christiane ;

Cuilliere-Dartigues, Peggy ;

Baia, Maryse ;

Briere, Josette ;

Delarue, Richard ;

Canioni, Danielle ;

Salles, Gilles ;

Parrens, Marie ;

Belhadj, Karim ;

Fabiani, Bettina ;

Recher, Christian ;

Petrella, Tony ;

Ketterer, Nicolas ;

Peyrade, Frederic ;

Haioun, Corinne ;

Nagel, Inge ;

Siebert, Reiner ;

Jardin, Fabrice ;

Leroy, Karen ;

Jais, Jean-Philippe ;

Tilly, Helve ;

Molina, Thierry Jo ;

Gaulard, Philippe .

BLOOD, 2015, 126 (22) :2466-2474

← 1 2 3 4 →